EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome

Yanming Zhang iD, Gaoxiu Yu, Cong Wang, Jingwen Song, Junmei Liu, Feng Chen

Clinical Cardiology · 2025-12 · 48 (12)

DOI: 10.1002/clc.70232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Cardiology, online erschienen am 11.12.2025. Verfasst von Yanming Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Changhai Hospital, Naval Military Medical University, Shanghai, Yangpu, People's Republic of China. Hauptthemen laut MEDLINE: Ticagrelor, Acute Coronary Syndrome, Cytochrome P-450 CYP3A, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Naval Medical University Medical New Technology Cultivation Project, Efficacy Prediction and Patient Screening Strategy for CCM Based on the Levosimendan Treatment Response Rate in Heart Failure Patients, Mechanism Study on Improving Post-Myocardial Infarction Cardiac Function by Knocking Down DNM3OS to Target TFAM and Promote Myocardial Mitochondrial Gene Expre….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dual antiplatelet therapy with aspirin and a P2Y₁₂ inhibitor is standard for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention. While ticagrelor offers superior efficacy in reducing ischemic events compared to clopidogrel, its use is limited by a higher incidence of dyspnea, an adverse reaction whose underlying predictors remain incompletely understood. Genetic variations in CYP3A4/5, the principal enzymes responsible for ticagrelor metabolism, may influence interindividual susceptibility to this side effect.

Methods

In a prospective cohort of 385 ACS patients on ticagrelor, we genotyped CYP3A4 rs2242480 and CYP3A5 rs776746. Outcomes (dyspnea per CTCAE v5.0, bleeding per BARC criteria) were assessed over 1 year. Associations were analyzed using logistic regression and GMDR modeling.

Results

The CYP3A5 rs776746 genotype strongly predicted dyspnea risk. Compared to the CC genotype, CT and TT genotypes were associated with a 55% and 91% reduced risk, respectively. Carriers of the combined CT/TT genotypes had a 63% lower risk. CC genotype carriers (poor metabolizers) exhibited a 2.3‐fold higher dyspnea incidence. No significant associations were found for CYP3A4 rs2242480 or for bleeding outcomes.

Conclusion

The CYP3A5 rs776746 CC genotype is a significant genetic biomarker for ticagrelor‐induced dyspnea. Pre‐emptive genotyping could enable personalized antiplatelet therapy, such as alternative P2Y₁₂ inhibitors for high‐risk CC carriers, to improve patient safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TicagrelorAcute Coronary SyndromeCytochrome P-450 CYP3APolymorphism, Single NucleotidePlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsDyspneaPharmacogenomic VariantsHumansMaleFemaleProspective StudiesAgedMiddle AgedHemorrhageRisk FactorsGenotypePercutaneous Coronary Intervention

Substanzen

TicagrelorCytochrome P-450 CYP3APlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsCYP3A5 protein, humanCYP3A4 protein, human

Autor:innen und Institutionen

  • Department of Cardiology, Changhai Hospital, Naval Military Medical University, Shanghai, Yangpu, People's Republic of China.

ORCID-Profile: Yanming Zhang

Förderung

  • Naval Medical University Medical New Technology Cultivation Project
  • Efficacy Prediction and Patient Screening Strategy for CCM Based on the Levosimendan Treatment Response Rate in Heart Failure Patients
  • Mechanism Study on Improving Post-Myocardial Infarction Cardiac Function by Knocking Down DNM3OS to Target TFAM and Promote Myocardial Mitochondrial Gene Expre…
  • Naval Medical University Youth Cultivation Project
  • The Function and Mechanism of TTP in Mediating TNFα and GM-CSF mRNA Degradation and Translation Inhibition via AU-rich Elements to Attenuate Cardiomyocyte Apop…

Zitieren

APA

Zhang, Y., Yu, G., Wang, C., Song, J., Liu, J., & Chen, F. (2025). Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome. Clinical Cardiology, 48(12). https://doi.org/10.1002/clc.70232

Vancouver

Zhang Y, Yu G, Wang C, Song J, Liu J, Chen F. Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome. Clinical Cardiology. 2025;48(12). doi:10.1002/clc.70232

BibTeX
@article{Zhang2025,
  author = {Zhang, Yanming and Yu, Gaoxiu and Wang, Cong and Song, Jingwen and Liu, Junmei and Chen, Feng},
  title = {Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome},
  journal = {Clinical Cardiology},
  year = {2025},
  volume = {48},
  number = {12},
  doi = {10.1002/clc.70232}
}
Kostenlos starten →